Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: A randomized clinical trial

JAMA Dermatology

Volumn 150, Issue 1, 2014, Pages 47-50

  Lenane, Patsy ^a   Macarthur, Colin ^b   Parkin, Patricia C ^b   Krafchik, Bernice ^b   DeGroot, Julie ^b   Khambalia, Amina ^b   Pope, Elena ^b  

^a CHILDREN S UNIVERSITY HOSPITAL   (Ireland)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; HYDROCORTISONE;

ADOLESCENT; ALOPECIA AREATA; APPLICATION SITE BURNING; ARTICLE; CANADA; CHILD; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCALP; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ALOPECIA AREATA; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; CLOBETASOL; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892775270     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.5764     Document Type: Article

References (11)

1. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70(7):628-633.
2. Nanda A, Al-Fouzan AS, Al-Hasawi F. Alopecia areata in children: a clinical profile. Pediatr Dermatol. 2002;19(6):482-485.
3. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55(3):438-441.
4. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008;(2):CD004413.
5. Rice J. Mathematical Statistics and Data Analysis. 2nd ed. Belmont, CA: Duxbury Press; 1994.
6. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
7. Al-Mutairi N, Eldin ON. Clinical profile and impact on quality of life: seven years experience with patients of alopecia areata. Indian J Dermatol Venereol Leprol. 2011;77(4):489-493.
8. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916-926.
9. RoyerM, Bodemer C, Vabres P, et al. Efficacy and tolerability ofmethotrexate in severe childhood alopecia areata. Br J Dermatol. 2011;165(2):407-410.
10. Farshi S, Mansouri P, Safar F, Khiabanloo SR. Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? a pilot study. Int J Dermatol. 2010;49(10):1188-1193.
11. Salsberg JM, Donovan J. The safety and efficacy of diphencyprone for the treatment of alopecia areata in children. Arch Dermatol. 2012;148(9):1084-1085.